Impact of Topical Aromatherapy on Postoperative Quality of Recovery After Lung Resection (AromaQoR)
Evaluation of the Impact of Aromatherapy Applied to the Skin as a Complementary Treatment on the Quality of Recovery (QoR) Following Lung Resection
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
Lung cancer is the leading cause of cancer mortality in France. Lung resection is the standard treatment for early-stage or locally advanced non-small cell lung cancer, but it remains a very painful procedure with a high risk of complications and a morbidity rate of around 30%. Enhanced Recovery After Surgery (ERAS) protocols have reduced morbidity and mortality through standardized perioperative care. Early and optimal pain control is essential to promote rapid mobilization, limit complications, and prevent chronicity. Despite multimodal management, acute, neuropathic, and chronic pain remain common after lung resection and impair the quality of recovery.
Complementary approaches, such as aromatherapy, are increasingly used to support conventional treatments, sometimes reducing the use of morphine derivatives and their adverse effects. Lavender (Lavandula angustifolia) essential oil and its main components, linalool and linalyl acetate, whose antinociceptive, anti-inflammatory, and anxiolytic properties are well documented, is of particular interest. Our study will evaluate the effect of daily application of 5% lavender essential oil (AromaQoR) to the skin around the surgical wound for three days following surgery on improving the quality of recovery.
The surgeon preselects eligible patients and the coordinating nurse ("IDEC") presents the study to them during a preoperative interview. The day before surgery, the IDEC obtains consent, has the QoR-15F completed, and performs an AromaQoR skin test. On the morning of surgery, only patients without allergic reactions are included and then randomized into two groups: placebo (PL) or intervention (AT). From D0 to D2, the intervention (placebo or AromaQoR) is applied every evening, while the QoR-15F questionnaire is collected daily by a different team. Pain scores (EN, DN4) are measured regularly, with only those taken the following morning being recorded, and all rescue analgesics are recorded. A post-operative consultation is conducted three weeks after discharge, during which the IDEC measures the EN and DN4 and collects the QoR-15F questionnaire completed by the patient. This consultation marks the end of follow-up for the trial.
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: claudia Lavedan
- Telefonnummer: +33 5 67 77 18 74
- E-Mail: lavedan.c@chu-toulouse.fr
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Adults aged 18 years or older,
- undergoing scheduled lung resection for diagnostic or therapeutic purposes
- able to give free, informed, signed consent (no later than the day of inclusion and before any examination required by the research)
- person affiliated with or beneficiary of a social security system.
Exclusion Criteria:
- Patients with chronic pain prior to surgery
- patients undergoing daily pain relief treatment prior to surgery
- patients using essential oils applied to the skin for pain relief.
- In relation to aromatherapy:
- history of allergy to essential oils
- atopic skin
- known allergies
- asthma
- pregnant or breastfeeding women
- nut allergies (in relation to sweet almond oil)
- individuals who are vulnerable or deprived of their liberty by judicial or administrative decision
- patients participating in other interventional studies on pain.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Placebo-Komparator: PL =placebo
The PL group: In addition to standard pain relief treatments, the PL group will receive topical application of sweet almond oil around the operated area at 9 p.m. from day 0 to day 2.
|
topical application of sweet almond oil around the operated area
|
|
Experimental: AT = aromatherapy
The AT group: in addition to standard analgesic treatments, the AT group will receive topical application of the "AromaQoR" formulation, containing lavender essential oil (Lavandula angustifolia) diluted to 5% in sweet almond vegetable oil around the operated area at 9 p.m. from day 0 to day 2.
|
topical application of the "AromaQoR" formulation, containing lavender essential oil (Lavandula angustifolia) diluted to 5% in sweet almond vegetable oil around the operated area
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in the total QoR-15F
Zeitfenster: day 2
|
Change in the total QoR-15F score (Recovery Quality score) on postoperative day 2 (measured in the evening, as it assesses, among other things, activity during the day) compared to the baseline value obtained the day before surgery, day -1, between the two groups.
|
day 2
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in the total QoR-15F score (Recovery Quality) on postoperative Day 1 (evening)
Zeitfenster: Day 1
|
Change in the total QoR-15F score (Recovery Quality) on postoperative D1 (evening) compared to the baseline value on Day-1
|
Day 1
|
|
Change in the total QoR-15F score (Recovery Quality) on postoperative Day 3 (evening)
Zeitfenster: Day 3
|
Change in the total QoR-15F score (Recovery Quality) on postoperative Day 3 (evening) compared to the baseline value on Day-1
|
Day 3
|
|
Change in the total QoR-15F score 3 weeks after discharge (postoperative consultation)
Zeitfenster: Week 3
|
Change in the total QoR-15F score 3 weeks after discharge (postoperative consultation) compared to the baseline value on D-1
|
Week 3
|
|
Change in pain score at Day 0 (= day of surgery)
Zeitfenster: Day 0
|
pain score measured by numerical scale (EN) at each measurement time point compared to Day-1
|
Day 0
|
|
Change in pain score at from postoperative Day 1 to postoperative Day 3 (morning, evening, night)
Zeitfenster: Day 3
|
pain score measured by numerical scale (EN) at each measurement time point compared to Day-1
|
Day 3
|
|
Change in pain score at 3 weeks after discharge (day of postoperative consultation).
Zeitfenster: week 3
|
pain score measured by numerical scale (EN) at each measurement time point compared to Day-1
|
week 3
|
|
Quantification of the consumption of Nefopam
Zeitfenster: day 3
|
number of ampoules consumed per day.
|
day 3
|
|
Quantification of the consumption of morphine derivatives (prescribed as a second-line treatment if Nefopam is ineffective)
Zeitfenster: day 3
|
number of tablets consumed per day
|
day 3
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- RC31/25/0027
- 2025-A01016-43 (Andere Kennung: Numéro ID-RCB)
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Schmerzen
-
Brixton Biosciences, Inc.MCRANoch keine RekrutierungGreater Trochanteric Pain Syndrome | Seitliche Hüftschmerzen | Greater Trochanteric Pain Syndrome beider unteren Extremitäten
-
Kanuni Sultan Suleyman Training and Research HospitalRekrutierungGreater Trochanteric Pain SyndromeTürkei (türkiye)
-
Foundation IRCCS San Matteo HospitalAktiv, nicht rekrutierendGreater Trochanteric Pain Syndrome beider unteren ExtremitätenItalien
-
Future University in EgyptAbgeschlossen
-
Ankara Etlik City HospitalAbgeschlossenGluteale Tendinopathie | Greater Trochanteric Pain Syndrome | Tiefes Gluteal-SyndromTürkei (türkiye)
-
Camilo Jose Cela UniversityAbgeschlossenMyofascial Pain Syndrom (MPS)Spanien
-
Sahmyook UniversityAbgeschlossenMyofascial Pain Syndrom (MPS)Südkorea
-
University of California, DavisNational Institutes of Health (NIH); National Center for Complementary and Integrative...Noch keine RekrutierungChronischer Kreuzschmerz (cLBP) | Myofascial Pain Syndrom (MPS)Vereinigte Staaten
-
Gazi UniversityAbgeschlossenGesäß-Tendinitis | Greater Trochanteric Pain Syndrome beider unteren ExtremitätenTruthahn
-
Palacky UniversityRekrutierungTemporomandibular Joint Dysfunction; Myofascial Pain Syndrome; Orofacial Pain; Musculoskeletal DisordersTschechien